CSBio CSBio

X
[{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO\u00ae, the First and Only Single-Dose Treatment for Acute Otitis Externa","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"ALK"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            ALK

            Contact Supplier
            • Deals

            Details:

            Under the terms of the agreement, ALK will have exclusive rights to promote OTIPRIO for AOE to office-based healthcare professionals in the U.S. including ENT physicians, pediatricians and select primary care physicians.

            Lead Product(s): Ciprofloxacin

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Otiprio

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Otonomy

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY